ContextVision AB: Transactions made under the buy-back programme

Summary by AI ^BETAClose X

ContextVision AB has provided an update on its share buy-back program, which was initially announced for up to NOK 10,000,000 and extended until May 11, 2026. Between March 9 and March 16, 2026, the company repurchased 161,167 shares for a total of NOK 490,257.32, with daily weighted average prices ranging from NOK 2.9258 to NOK 3.2082. Including previous transactions, the program has accumulated 1,188,241 shares at an average price of NOK 3.8358, totaling NOK 4,595,946.91. Following these transactions, ContextVision now holds 2,429,698 own shares, representing 3.14% of its share capital.

Disclaimer*

Oslo, 17 March 2026 – On 3 September, ContextVision AB (“ContextVision” or the “Company”) announced a share buy-back programme of up to NOK 10,000,000, with a maximum of 4,000,000 shares, in the period from 5 September 2025 to 5 March 2026. On 18 February 2026, ContextVision AB announced an extension of the share buy-back programme with unchanged terms, until May 11 2026.
DNB Carnegie, acting under the mandate from ContextVision, has carried out the following transactions under the buy-back programme:

Date	Aggregated daily volume (number of shares)	Weighted average share price per day (NOK)	Total daily transaction value (NOK)
2026-03-09	25 322	2,9258	74 717,63
2026-03-10	26 397	3,0097	79 542,08
2026-03-11	27 968	3,0572	85 864,56
2026-03-12	28 398	3,1411	89 314,55
2026-03-13	24 920	3,2082	80 865,40
2026-03-16	28 162	3,1835	89 645,28
2026-03-17	0	3,1516	0,00
Previously disclosed buy-buys under the programme (accumulated)	1 027 074	3,8769	4 095 997,42
Accumulated under the buy-back programme	1 188 241	3,8358	4 595 946,91

Following the completion of the above transactions, ContextVision owns a total of 2 429 698 of own shares, corresponding to 3,14% of ContextVision’s share capital.

An overview of all transactions made under the buy-back programme that have been carried out during the abovementioned time period is attached to this report and available at www.newsweb.no.
This is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Richard Hallström, CFO, on the time and date provided.

For further information, please contact:
Richard Hallström, CFO
Email: richard.hallstrom@contextvision.com

About ContextVision AB:
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.